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AbStrAct
Anthrax, a zoonotic disease caused by Bacillus anthracis is important for biowarfare as well as public health 
point of view. The virulence factors of B. anthracis are encoded by the two plasmids, pXO1 and pXO2. Protective 
antigen (PA), an 83 kDa protein encoded by pXO1 along with lethal factor (LF, 90 kDa) or edema factor (EF, 89 
kDa), makes the anthrax toxin responsible for causing the disease. Current detection and diagnostic systems for 
anthrax are mostly based on PA, a potential biomarker of B. anthracis. The objective of the present study was to 
produce and purify the PA for development of a sandwich ELISA for its detection. In this study, pYS5 plasmid 
containing the full PA gene was transformed into an 8 proteases deficient Bacillus anthracis host BH480. The PA 
was produced under shake flask conditions and purified using the gel filtration chromatography. The reactivity of 
PA with rabbit and mouse anti-PA antibodies was confirmed by Western blotting. The antibodies were purified and 
used for the development of a sandwich ELISA for detection of PA. The detection sensitivity of ELISA was found 
to be 3.9 ng/ mL PA.
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1. IntroDuctIon
Bacillus anthracis, a Gram-positive, spore-forming 
bacterium causes anthrax in higher mammals including 
human. Depending on the route of exposure, anthrax can be 
of three types viz. cutaneous, gastrointestinal or inhalational1. 
The inhalational (pulmonary) anthrax is considered to be the 
most severe form among the three  due to its high mortality 
rate. B. anthracis forms the spores which are highly resistant 
under extreme harsh environmental conditions and persist for 
many decades2. B. anthracis spores can easily be aerosolised 
and disseminated. Therefore, B. anthracis is considered as a 
category ‘A’ bio-threat agent3,4.
B. anthracis contains two large plasmids. pXO1 and 
pXO2 encoding the toxigenicity and pathogenicity factors, 
respectively. The pXO1 encodes protective antigen (PA), 
edema factor (EF) and lethal factor (LF)5, whereas the pXO2 
encodes poly-γ-D-glutamic acid capsule having anti-phagocytic 
property. PA, LF and EF are individually non-toxic, however, 
LF and EF in association with PA make the lethal toxin and 
edema toxin, respectively6. 
PA is the central factor of the tripartite complex, and 
hence has always been  the major target for the development 
of anthrax vaccine or diagnostic assays7-10. The PA protein is 
secreted in medium during the growth of B. anthracis in vitro 
but the amount of PA is very low and also have small amount 
of EF and LF11. Hence, due to contamination of PA with 
other toxins it can’t be used for diagnosis purpose. Moreover, 
handling of B. anthracis for production and purification 
of native PA is risky. To overcome this problem. PA gene 
has been transformed into various hosts for the production 
of recombinant PA such as Esherichia coli12-14, Bacillus 
subtilis15,16, B. anthracis17,18, Bacillus brevis11, Baculovirus and 
Vaccinia Virus19, and Pseudomonas fluorescens20. However, 
each expression system has some limitations. B. anthracis and 
B. subtilis produce various proteases in the growth medium 
leading to degradation of PA. 
The early diagnosis of anthrax increases the likelihood of 
survival and recovery of the patient by timely treatment. Most 
of the serodiagnostic assays for anthrax are based on detection 
of antibodies against PA or LF21,22. However, these methods 
can be employed only after development of antibody response 
in patient post infection. For the early diagnosis, anthrax toxins 
are the best target due to early secretion of toxin in the course 
of disease before detectable bacteremia or immune response8,23. 
In an earlier developed monoclonal antibody based capture 
sandwich ELISA, as low as 1 ng/ml of PA could be detected 
from the serum of Guinea pig and rabbit24. In another study, 
10 pg/ml of PA could be detected in artificially spiked human 
blood samples by surface plasmon resonance8  Hence, direct 
detection of toxin can provide a timely diagnosis compared to 
serology or culture-dependent methodologies. In the present 
study, pYS5 plasmid containing full PA gene was transformed 
into an 8 proteases deficient B. anthracis host BH480. The 
PA was produced and purified from the recombinant host and 
used for the production of polyclonal antibodies in rabbit and 
mouse. The antibodies were further used for the development 
of a sandwich ELISA for detection of  PA. 
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2. MAtErIALS AnD MEthoDS
2.1 Strains and Plasmids 
B. anthracis Ames BH480 strain25 (with the genotype 
pXO1-, pXO2-, Spo0A- (GBAA_4394), NprB- (GBAA_0599), 
TasA- (GBAA_1298), Cam- (GBAA_1290), InhA1- 
(GBAA_1295), InhA2- (GBAA_0672), MmpZ- (GBAA_3159), 
CysP1- (GBAA_1995), VpR- (GBAA_4584), and the pYS5 
plasmid containing original pagA promoter from pXO1, 
including 162 bp of B. anthracis DNA upstream of the PA 
start codon used in this study were obtained from Institute 
of Genomics & Integrative Biology, Delhi. The pYS plasmid 
was transformed into dam- and dcm- E. coli SCS110 strain. 
The non-methylated plasmid of SCS110 was then transformed 
into the electro-competent B. anthracis BH480 strain, which is 
avirulent and sporulation defective strain25.
2.2 reagents and chemicals
All culture media for protein production were from Difco 
(USA). The Superdex 200 used for gel filtration column was 
purchased from GE Healthcare (Sweden). The adjuvant, HRP 
conjugated secondary antibodies and all other chemicals were 
purchased from Sigma Chemical Co. (uSA) unless indicated 
otherwise.
2.3 Ethical Statement 
All animal care and experimental procedures were 
conducted as per the approved protocols of Institutional Animal 
Ethics Committee (IAEC) of DRDE (Reg. No.37/Go/C/1999/
CPCSEA) and Institutional Biosafety Committee (Protocol 
no. IBSC/12/BT/AKG/22). All the experimental mice were 
maintained in pathogen free facility. 
2.4 Production and Purification of PA from B. 
anthracis
The recombinant PA from B. anthracis was expressed and 
purified as described earlier with minor modifications26. Briefly, 
a 50 mL of LB broth containing 25 µg/mL of kanamycin was 
inoculated with B. anthracis BH480. After 8 h incubation at 
37 °C, 5% (v/v) of the culture was further inoculated into 500 
mL of super broth (SB) medium supplemented with 0.5% 
bicarbonate and incubated for 16 h at 37 °C. After centrifugation 
at 15317 x g at 4 °C for 20 min, the supernatant containing PA 
was collected.
The PA protein was precipitated with 60 % ammonium 
sulphate at 4 °C and recovered by centrifugation at 1860 x g 
for 20 min. Ammonium sulphate precipitation concentrates the 
protein as well as some media components also. The media 
components interfere in column during protein purification, 
therefore, media components were removed by dialysis. 
The pellet was re-suspended in Phosphate buffer saline 
containing 20 % glycerol followed by dialysis in the same 
buffer. Further, the dialysed protein was purified using gel 
filtration chromatography27. The Superdex 200 column was 
pre-equilibrated with 50 mM phosphate buffer (pH 7.4) at a 
constant linear flow rate of 50 cm/h. Dialysed protein was 
loaded to the pre-equilibrated column. The purified protein 
was eluted from the column using 50 mM phosphate buffer 
containing 20% glycerol. Elutes were analysed by SDS-PAGE 
and stored at -80 °C until further use.
To increase the stability of the PA protein in the buffer, 
20% glycerol was added in the buffer as the glycerol increases 
the stability as well as inhibits the protein aggregation in 
vitro28,29. 
2.5 Production and characterisation of anti PA 
rabbit and Mouse Polyclonal Antibody (pAb)
 New Zealand white rabbits and BALB/c mice were used 
for production of anti-PA polyclonal antibodies as described 
elsewhere30. Final bleeding of rabbit and mice was carried out 
on day 60. The sera were separated from blood and used in 
Western blot and ELISA. 
The purified PA was run on 12 % SDS-PAGE and 
transferred on PVDF membrane and incubated with 1:2000 
dilution of anti-PA mouse or rabbit serum as described 
earlier30. The membranes were incubated with anti-mouse or 
anti-rabbit IgG HRP conjugate (1:10000) for 1 h at 37 °C, and 
developed with 3,3′-Diaminobenzidine/H2O2 substrate solution 
for 2 min at room temperature.
Antibody titre of rabbit and mouse sera was evaluated 
by indirect ELISA as described earlier31. Sera of rabbit and 
mouse collected before immunisation were used as control. 
The antibody titer was expressed as reciprocal of the endpoint 
dilution. For the development of ELISA antibodies were 
purified using protein G column  and the purity was determined 
on  SDS-PAGE.
2.6 Development of Sandwich ELISA for Detection 
of PA
A sandwich ELISA was developed for detection of PA 
as described earlier32. Briefly, ninety-six-well ELISA plates 
were coated overnight with purified rabbit anti-PA antibodies 
(200 ng/well) in carbonate-bicarbonate coating buffer (0.06 M 
Na2CO3 and 0.14 M NaHCO3), pH 9.5 at 4 °C. Plates were 
then washed three times with 0.1% tween-20 in  PBS, pH 7.4 
(PBS-T) followed by blocking with 5% skimmed milk protein 
(SMP) at 37 °C for 1 h. After washing with PBS-T, different 
concentrations of purified PA starting from 200 ng to 0.19 ng/ 
well were added and incubated at 37 °C for 1 h. The plates were 
again washed and incubated with 200 ng/well anti PA mouse 
polyclonal antibody in 1% SMP (in  PBS) for 1 h at 37 °C. 
Anti PA mouse polyclonal antibodies were used as a revealing 
antibodies which were probed with rabbit anti-mouse HRP-
conjugate (1:4000)  TMB substrate was added after incubation 
at 37 °C for 1 h and kept at 37 °C for 10 min. The plate was 
read at 450 nm after adding 50 µl of 2.5 N H2SO4 to each well. 
The samples were tested in triplicate. 
3. rESuLtS
3.1 Production and Purification of PA
In this study,  we used the B. anthracis strain BH480, 
which is asporogenic, lacks both the virulence plasmids, and is 
deleted for 8 extracellular proteases. The strain was transformed 
with PA gene containing pYS5 plasmid.
A protein band of ~83 kDa on the SDS PAGE of 
supernatant confirmed the expression of PA (Fig. 1). The 
ammonium sulphate precipitated protein was analysed by 
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SDS-PAGE. No band was observed at ~83 kDa in supernatant, 
while an intense band of PA was observed in the pellet 
(Fig. 2(a)). The precipitated protein was dialysed and purified 
by gel filtration column and a single band of ~83 kDa was found 
on SDS-PAGE (Fig. 2(b)). The elutes containing PA protein 
were pooled and the concentration was checked by BCA assay. 
A final protein concentration of 1.0 mg/ mL was made and 
stored at -80 °C for further use. 
determined by ELISA. The antibody titre of rabbit serum was 
1: 256000 with PA in indirect ELISA. The antibody raised in 
mouse serum also exhibited a titre of 1: 256000.
3.3 Development of Sandwich ELISA
For the development of sandwich ELISA, the antibodies 
were purified from the serum and checked by SDS-PAGE. 
In the antigen capture ELISA, rabbit antibodies were used 
for capturing and mouse antibodies were used as revealing 
antibodies. An antigen concentration from 200 ng to 0.19 ng 
per well was tested. The OD vs PA concentration profile is 
shown in Fig. 4. PA as low as 3.9 ng/mL could be detected by 
sandwich ELISA (Fig. 4). 
4. DIScuSSIon
B. anthracis is listed as a ‘Category A’ biothreat agent 
by the Center of Disease Control and Prevention (CDC), 
uSA. Surveillance of B. anthracis being an agent of bio-
warfare as well as public health importance in several agrarian 
Figure 4. Detection sensitivity of recombinant PA by sandwich 
ELISA using polyclonal antibodies.
Figure 1. SDS-PAGE profile of expressed PA. Lane 1, MW 
marker; lane 2 culture supernatant containing PA. 
Figure 2. SDS-PAGE profile for ammonium sulphate precipitated 
and purified protein. (a) Ammonium sulphate 
precipitation of PA. Lane 1, MW marker; lane 2, 
Supernatant after ammonium sulphate precipitation; 
lane 3, Pellet of ammonium sulphate precipitate. (b) 
Purified recombinant PA. Lane 1, MW marker; lane 
2, Purified protein. 
3.2 Production and characterisation of Anti PA 
rabbit and Mouse Polyclonal Antibodies 
The PA raised high levels of specific antibody titer. 
Western blot was performed to check the reactivity of the anti-
PA rabbit and mouse sera with purified recombinant PA of B. 
anthracis.  The anti-PA rabbit and mouse sera gave reactivity 
with the PA of B. anthracis in Western blot (Fig. 3). 
The antibody titres of rabbit and mouse sera were 
Figure 3.  reactivity of anti-PA sera with purified PA by Western 
blot. Lane 1, MW marker; lane 2, anti-PA rabbit 
sera; lane 3, anti-PA mouse sera. 
(b)(a)
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countries is very important for timely detection of epidemics33. 
Apart from worldwide cases, in India, both sporadic cases 
and outbreaks of anthrax are reported regularly from many 
states4.  
There are well established antibiotic regimens for the 
treatment or recovery of anthrax in human as well as animals. 
However, anthrax vaccination is the most effective method of 
prevention before exposure. Anthrax vaccine adsorbed (AVA) 
is the licensed vaccine for people at high risk of exposure. 
However, empirically it is not possible to use anthrax vaccine 
for mass vaccination. Hence, early diagnosis is very important 
to post exposure prevention methods to curtail the spread of 
disease as well as for  patient management4. 
Purified recombinant protein is required for diagnostic 
use. In the present work, pYS5 plasmid containing PA gene 
was transformed in B. anthracis BH480, which lacks 8 protease 
enzymes and prevents proteolytic cleavage of PA in the growth 
media. To enhance the production of PA and its stability, 
various manipulations have been done in B. anthracis. Non-
sporogenic, protease-deficient, avirulent BH44518 and BH46034 
strains were developed. B. anthracis strain BH480 is 8 protease 
deficient strain for production of PA in native conditions25. For 
the production of PA in Bacillus, various shuttle systems have 
also been constructed. The shuttle vector pYS5 from Bacillus 
– E. coli was constructed to clone a recombinant PA in the host 
cell35.
The culture supernatant was precipitated by ammonium 
sulphate to concentrate the PA. The precipitated protein was 
re-suspended in PBS buffer containing 20 % glycerol and 
dialysed before purification. A single step chromatography 
purification process was employed for purification of PA. The 
purified protein yielded a single band with expected molecular 
weight of ~83 kDa on SDS-PAGE (Fig. 2(b)).
The purified protein was used to generate polyclonal 
antibodies in rabbit and mouse. The sera reacted with PA in 
Western blot. The antibody titer was checked by indirect 
ELISA. The purified antibodies were used for development 
of sandwich ELISA using rabbit antibodies for capturing 
and mouse antibodies for revealing. The detection limit 
of developed ELISA was 3.9 ng/mL in dilution buffer 
(Fig. 4). Previously, anti-PA monoclonal antibodies were 
used to develop the sandwich ELISA and as low as 1 ng/ml 
of PA could be detected from the serum of rabbit and Guinea 
pigs24. By surface plasmon resonance (SPR), as low as 10 pg/
ml of PA was detected from the human serum artificially spiked 
with PA8.
The antibodies and the sandwich ELISA can be further 
used for detection of PA in the clinical serum samples. Earlier, 
it has been reported that PA in the infected sera could serve 
as a reliable marker of infection36. It was observed that there 
is a direct correlation between the quantitative of PA and 
level of bacteraemia in the sera of both rabbit and guinea pig 
models36.
In conclusion, the recombinant PA was produced from B. 
anthracis and purified using gel filtration chromatography in 
this study. Sandwich ELISA developed using the polyclonal 
antibodies against the purified PA exhibited its potential for 
the detection of PA. Hence, the ELISA can further be used for 
detection of PA in the clinical samples. 
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